Abstract. In the wake of recent progress in understanding the genetic pathways involved in the development of brain tumors, a major goal is to correlate molecular data with clinical outcome, survival, and response to treatment modalities. This is of particular importance among the pediatric population. Reliable prognostic factors could potentially permit a tailoring of therapy in that only patients with the most aggressive tumors would receive the most intense treatments. A survey of publications about prognosis-related molecular features among pediatric brain tumors revealed 74 series, of which 46 presented statistically significant outcome-associated parameters as defined by a p value Ͻ0.05. Most investigations revealing significant prognosisrelated features were performed on medulloblastomas (34 publications), followed by astrocytic tumors (6 publications) and ependymomas (5 publications). Promising approaches and molecular markers include gene expression profiles, DNA ploidy, loss of heterozygosity and chromosomal aberrations as detected by CGH and FISH (1q, 17p, 17q), as well as oncogenes/ tumor suppressor genes and their proteins (TP53, PTEN, c-erbB2, N-myc, c-myc) , growth factor and hormonal receptors (PDGFRA, VEGF, EGFR, HER2, HER4, ErbB-2, hTERT, TrkC), cell cycle genes (p27) and cell adhesion molecules, as well as factors potentially related to therapeutic resistance (multi-drug resistance, DNA topoisomerase IIalpha, metallothionein, Pglycoprotein, tenascin). This review discusses the predictive potential of molecular markers for clinical outcome and their influence on therapeutic decision-making among children with brain tumors.
INTRODUCTION
Brain tumors amount to less than 2% of all malignant neoplasms. However, they account for approximately 20% of all childhood cancers, thus ranking second in incidence after leukemias, and are the leading cause of cancer morbidity and mortality among children. Although there are several demographic, clinical, and therapeutic parameters (e.g. patient age and gender, tumor location, extent of tumor resection and application of adjuvant radio-and/or chemotherapy, which have highly significant prognostic bearing for some pediatric brain tumors), predicting the clinical course and outcome among children with central nervous system (CNS) tumors has been difficult.
In the wake of recent progress in the understanding of molecular pathways involved in the development of brain tumors, a major goal is to correlate genetic data with clinical outcome, survival, and response to treatment modalities. On June 28, 2004 , PubMed listed 8,880 publications containing the words ''prognosis/outcome'' and ''brain/CNS tumor.'' This statistic confirms that prognosis-oriented studies are plentiful in the published record; however, many weakly conclude that the investigated factors ''may'' be prognostic, with the plethora of prognostic studies leaving one disappointed by how few parameters, if any, have been accepted into clinical practice.
The first significant development in clinically relevant molecular classification of brain tumors has been the recently recognized association between the combined loss of chromosomes 1p and 19q and the therapeutic responsiveness of a subset of gliomas displaying oligodendroglial features, that is, anaplastic oligodendrogliomas and oligoastrocytomas (1) . Furthermore, a multidimensional scaling analysis of gene expression profiles among a whole range of gliomas revealed survival-relevant clinical subsets (2) , showing that contemporary molecular techniques offer the promise of improved tumor classification and resultant patient stratification for treatment and prognosis.
Prognostic indicators of cancer are most relevant in reference to tumors for which there is reasonable expectation for cure or as a guide for appropriate therapy rather than a timeline for tumor progression and death. The accuracy of prognostic indicators is a crucial issue-in particular among childhood cancers-because some therapy regimens can have deleterious effects, resulting in substantial long-term morbidity and neuropsychologic sequelae in the affected children. Ideally, reliable prognostic factors would in some cases and for some tumor entities permit a tailoring of therapy in that only patients with the most aggressive tumors would receive the most intense treatments, while children with less aggressive tumors would be treated effectively but spared the most devastating therapies, thereby improving their quality of life.
The following is a survey and literature review of prognosis-related molecular factors among pediatric CNS tumors and a discussion of their potential value as markers for predicting therapy response as well as patient outcome.
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A MEDLINE-guided survey of prognosis-related molecular markers in childhood brain tumors revealed a multitude of potentially clinically and prognostically relevant parameters among different entities sampled from 74 publications. Where possible, data of individual patients with given age under 18 years were included. However, larger cohorts of brain tumors where the individual patients' ages were not given but mainly dealt with pediatric cohorts or where the tumor entity could generally be regarded as ''pediatric'' (e.g. medulloblastomas, choroid plexus tumors) were also included. On the other hand, entities that generally affect adults rather than children (e.g. glioblastomas) were intensely scrutinized for patient age and only sampled if the series contained patients younger than18 years of age. Prognosis-related clinical (tumor location, duration of symptoms, and demographic data such as patient age and gender) and therapeutic factors (i.e. extent of surgical resection and adjuvant radio-and chemotherapy) were excluded from this study, as the impact of these parameters on clinical outcome among children with brain tumors has already been thoroughly investigated and defined among most entities.
Of the 74 series dealing with prognosis-related molecular features among pediatric brain tumors, 46 presented statistically significant outcome-associated parameters as defined by a p value Ͻ0.05 (Table 1) . Among the studies containing statistically significant data, sample sizes varied from 10 anaplastic astrocytomas (3) to 115 high-grade astrocytic tumors (4), of which the latter was the only cohort consisting of more than 100 cases (Table 1) . However, there were 17 series with more than 50 cases each, of which 13 dealt with medulloblastomas, 3 with ependymomas, and one with high-grade astrocytomas (Table  2 ). Not surprisingly given their incidence and clinical importance, most investigations revealing statistically significant outcome-associated parameters were performed on medulloblastomas (34 publications), followed by astrocytic tumors with 6 publications and ependymomas with 5, as well as one on choroid plexus tumors (Table  1) . Interestingly, after filtering and listing studies propagating highly significant prognostic factors-here arbitrarily defined by a p value Յ0.001-medulloblastomas were still the most prominent entity (9 out of 10 studies; Table 3 ). The highest significance was encountered in a cohort of 60 medulloblastomas for a low-risk, 8-gene pattern expression profile resulting in a better 5-year overall survival (p ϭ 0.000003) (5) .
In the preface to his ''intracranial tumors,'' Harvey Cushing stated in 1932 that ''the laying bare of one's mere mortality percentages, is only a start towards what will ultimately be called for: namely figures relating to the expectancy of those who survived tumor extirpation.'' (6) . Certain diagnoses made according to the current WHO classification of CNS tumors do allow predictions to be made about biological behavior and therapeutic options (7) . However, some tumors or subgroups of neoplasms lack a close correspondence between diagnostic label and uniform biological behavior or therapeutic response, in particular the most common malignant brain tumor in childhood, the medulloblastoma (8) . The paradigm of oligodendrogliomas with loss of chromosomes 1p and 19q showing better response to chemotherapy reflects a developing trend in tumor diagnosis for molecular analysis to supplement histopathological assessment. A recent microarray analysis determining expression of approximately 12,000 genes in a set of 28 primary glioblastomas and 22 anaplastic oligodendrogliomas in almost exclusively adult patients showed that when tumors were classified according to histology, the survival of patients with nonclassic glioblastoma and nonclassic anaplastic oligodendroglioma was not significantly different, whereas gene expressionbased classification was significantly associated with survival outcome (p ϭ 0.05) (9) . The class prediction model applied by the authors was capable of classifying highgrade, nonclassic glial tumors objectively and reproducibly and provided a more accurate predictor of prognosis than did pathological classification, suggesting that prediction models based on defined molecular profiles classify diagnostically challenging malignant gliomas in a manner that better correlates with clinical outcome than does standard pathology (9) . This trend has already been seen in the field of pediatric oncology where genetic analysis is an important part of the investigation of several solid tumors, such as MYCN amplification among neuroblastomas and t(2;13) or t(1;13) among rhabdomyosarcomas (8) .
One of the central tenets of modern oncology is that malignant tumors are the end result of a series of accumulated genetic alterations resulting in loss of control of the cell cycle. Much of this research has been stimulated by karyotypic and cytogenetic studies of tumors, which have demonstrated non-random genetic rearrangements involving specific chromosomes (10) . With the current explosion in molecular biology research, a diverse array of factors have been identified and investigated for their potential roles in neoplasia, including oncogenes, growth factors and their receptors, hormonal receptors, proliferation markers, apoptosis, cell cycle genes and cell adhesion molecules, as well as factors potentially related to therapeutic resistance. Furthermore, an increasing number of anticancer drugs are designed to target specific proteins in cell-signaling pathways, and the therapeutic potential of several of these agents is now being investigated. Thus, in order to improve outcome prediction in patients affected by tumors and to refine therapeutic decision-making, there is a strong need for identifying relevant biological correlates of tumor behavior.
The following is a discussion of molecular prognostic markers among pediatric brain tumors that have been investigated and published over the years and which may potentially be of clinical benefit. For reasons of clarity, data are presented in the order in which tumor entities are listed in the current WHO classification of tumors of the nervous tissue.
ASTROCYTIC TUMORS
Astrocytic tumors are among the most common CNS neoplasms in childhood and account for approximately 40% of lesions (7) . One study of 30 pediatric astrocytic tumors of various histologies found ploidy to be a statistically significant predictor of survival independent of tumor grade, age, gender, and extent of resection (11): DNA diploidy was demonstrated in 21 patients and aneuploidy in 9 patients, and of the patients with diploid tumors, 81% survived compared to only 33% among patients with aneuploid tumors (p Ͻ 0.011).
LOW-GRADE ASTROCYTIC TUMORS Pilocytic Astrocytoma and Subependymal Giant Cell Astrocytoma
No prognostic molecular features have yet been reported.
Pleomorphic Xanthoastrocytoma
Pleomorphic xanthoastrocytoma (PXA) are mainly encountered in the second decade of life and account for 1.9% of pediatric brain tumors (7) . DNA ploidy was found to have no correlation with outcome in 12 patients (12) . Similarly, no prognostic significance for TP53 mutations regarding malignant progression or recurrence has yet been established in 2 independent investigations (13, 14) . One PXA, which revealed multiple genetic alterations after comparative genomic hybridization (CGH), showed a poor prognosis; however, large series relating survival to chromosomal aberrations do not yet exist (10) .
Diffuse Fibrillary Astrocytoma
Fibrillary astrocytomas are fairly rare in childhood and make up 5% of CNS tumors encountered in this period (7) . An investigation of p53 status among 10 fibrillary astrocytomas WHO grade II and 11 anaplastic astrocytomas WHO grade III from patients under 18 years of age found the time of survival to be significantly shorter in immunopositive cases; however, immunopositivity was correlated with higher tumor grade, while no significant difference was found in each of the subgroups (15) .
HIGH-GRADE ASTROCYTIC TUMORS
Immunohistochemical expression of p53 was analyzed in 115 high-grade astrocytic tumors, among which a significant association between p53 overexpression and outcome was found independent of histologic features, age, sex, the extent of resection, and tumor location (4). The 5-year progression-free survival was 44% among the 74 patients with low p53 expression, and 17.6% among the 41 patients with p53 overexpression (p Ͻ 0.001), indicating that overexpression of p53 in malignant gliomas of childhood is strongly associated with an adverse outcome, possibly because p53-dependent pathways influence the cytotoxic effects of conventional chemo-and radiotherapy (4) . The study corroborated an earlier investigation by the same authors who had already encountered a significant association between p53 overexpression and a shorter progression-free and overall survival (p ϭ 0.019 and p ϭ 0.013) in a smaller cohort (16) .
In a similar vein, immunoreactivity for nuclear DNA topoisomerase IIalpha (TIIalpha), a novel marker of cell cycle turnover and a determinant of tumor cell resistance to chemotherapy, was investigated in a series of 17 pediatric high-grade gliomas (17): a cut-off labeling index of 12% was found to define 2 prognostic subgroups with profoundly worse 5-year progression-free (60% vs 8%; p ϭ 0.011) and overall survival (100% vs 8%; p ϭ 0.0038) for cases with an index Ͼ12%.
An assessment of TP53 mutations in 29 high-grade childhood astrocytomas presented a significant association between TP53 mutations and a poorer progressionfree survival (p ϭ 0.04), as well as a strong trend toward shorter overall survival (p ϭ 0.06) among patients with TP53 mutations with respective survival times of 6 and 16 months for TP53-mutated cases compared with 16 and 25 months for those without TP53 mutations (16) . However, a later mutational analysis of TP53 by the same group on a larger cohort of 121 cases found an-albeit not significant-association between TP53 mutations and outcome (4) . In another group of 39 high-grade astrocytomas, PTEN mutations were significantly associated with decreased survival among pediatric patients (p ϭ 0.006), regardless of patient age or tumor grade, whereas mutations of TP53 or amplifications of MDM2 and CDK4 were not significantly linked to outcome (p ϭ 0.49, p ϭ 0.8, and p ϭ 0.6, respectively) (18) .
Anaplastic Astrocytoma
Anaplastic astrocytomas account for 7.2% of childhood brain tumors (7) . A CGH study on 10 anaplastic astrocytomas of childhood found a significantly shorter survival for tumors showing gains of chromosome 1q (p Ͻ 0.05) (3).
Glioblastoma
Glioblastomas account for 7.2% of childhood brain tumors (7). In the setting of Turcot syndrome type 1 (autosomal dominant disorder characterized by simultaneous occurrence of colorectal polyps and glioblastomas), glioblastomas tend to show a remarkably longer survival time (27 vs 12 months) compared with sporadic cases (19) . Sources are listed in chronological order. Abbreviations: CSS, cause-specific survival; DFS, disease-free survival; EFS, event-free survival; OS, overall survival; PFS, progression-free survival; RFS, recurrence-free survival; n, sample size; nd, no data given, p, p value.
The underlying molecular genetics in this syndrome consist of mismatch repair errors involving genes such as hPMS2 (7p22), hMSH2 (2p16), or hMLH1 (3p21).
OLIGODENDROGLIAL TUMORS
Oligodendroglial tumors are exceedingly rare among children: a population-based study of 3,268 cases found a relative frequency of 1.1% among under 15-year olds (7) . Interestingly, combined losses of 1p and 19q-which are known to convey a therapy-related survival advantage in the adult population (1)-do not seem to predict a better clinical outcome among pediatric malignant gliomas with or without oligodendroglial differentiation (20) .
EPENDYMAL TUMORS
Ependymomas are the third most common tumor entity among childhood CNS neoplasms after pilocytic astrocytomas and medulloblastomas and account for approximately 10% of cases (7) . Although there have been numerous studies in the past decades trying to link survival or tumor progression and recurrence with molecular features, no unequivocal connection has arisen and factors predictive of outcome are far from being well established (for a review see [21] ). Thus, the identification of parameters with prognostic value in ependymomas to this day remains an important but controversial issue.
Korshunov et al investigated immunoexpression of chemoresistance-related proteins metallothionein, glutathione S-transferase pi, and P-glycoprotein in a sample of 76 intracranial ependymomas and found the progression-free survival time to be significantly shorter for immunonegative tumors of both grades: multivariate analysis revealed a decreased risk of recurrence for metallothionein-(p ϭ 0.005) and P-glycoprotein-positive tumors (p ϭ 0.02), indicating that the expression of these antibodies may be estimated as a predictor for local tumor progression (22) . The same authors also assessed 88 ependymomas for the expression of tenascin, vascular endothelial growth factor (VEGF) protein, epidermal growth factor receptor (EGFR), and p53 protein as well as the cyclin-dependent kinase inhibitor p27/Kip1 regarding their prediction potential for recurrence (23) . A classification regression tree analysis exhibited 2 groups of ependymomas consisting of low-grade/tenascin-negative (32 cases, 0% recurrence) and low-grade/tenascin-positive (10, 89% recurrence) cases with a dramatically different recurrence rate (23) . Whereas one study on 22 ependymomas found no statistical correlation between DNA index and outcome (24), a later series of 17 pediatric cases surprisingly demonstrated that the presence of diploid DNA was associated with poor clinical outcome and shortened survival times (p Ͻ 0.05) (25) . In 2 recent CGH studies, gain of 1q in a cohort of 86 ependymomas showed a significantly worse clinical outcome (p ϭ 0.049) compared with ependymomas without ϩ1q (26), whereas the other publication demonstrated that ϩ1q was strongly, albeit not significantly, associated with recurrence and a worse 5-year survival rate of 15% compared with 50% for tumors without ϩ1q (27) . Furthermore, tumors with 6 or less chromosomal imbalances had significantly worse outcome (5-year survival: 10%) than tumors with 13 or more chromosome imbalances (5-year survival: 77%; p ϭ 0.02) or even a balanced profile (5-year survival: 55%; p ϭ 0.05), indicating a potential role for cytogenetic analysis of ependymal tumors regarding outcome (27) .
Classic Ependymoma
In a study of 88 cases a positive immunohistochemical expression of tenascin, VEGF, and EGFR in low-grade ependymomas was associated with a significantly shorter progression-free survival time (23) .
Two recent CGH investigations found classic ependymomas with ϩ1q to occur in the posterior fossa of children and to be characterized by an aggressive clinical course (26, 27) , with ϩ1q not only associated with a poorer outcome but also strongly linked with tumor recurrence (27) . Although no CGH association of chromosomal aberration with benign versus anaplastic histology could be drawn, gains of 7q and 9p as well as losses of 17 and 22 were significantly more common in recurrent compared with primary ependymomas (28) .
Anaplastic Ependymoma
Immunohistochemical assessment of 88 ependymomas found a significant preponderance of expression of tenascin, VEGF, EGFR, and p53 protein in high-grade tumors (23) . They also revealed lower indices for cyclin-dependent kinase inhibitor p27/Kip1, and found progression-free survival to be significantly reduced for a p27 labeling index Ͻ20% and p53 positivity (p Ͻ 0.05) (23) . As in classic ependymomas, anaplastic ependymomas with gains of chromosome 1q also tended to occur in the posterior fossa of children and behave aggressively (26, 27) . They showed a significantly worse overall survival compared with cases without ϩ1q (p ϭ 0.0032) (26) , and-albeit not significantly-with tumor recurrence (27) .
CHOROID PLEXUS TUMORS
Choroid plexus tumors are intraventricular papillary neoplasms derived from choroid plexus epithelium and occur as choroid plexus papillomas and choroid plexus carcinomas with an intermediate atypical papilloma still to be defined and included in the WHO classification.
Choroid Plexus Papilloma
Generally, resection of choroid plexus papillomas is curative. However, analysis of DNA revealed that aneuploid choroid plexus papillomas had a worse prognosis than diploid papillomas and were associated with more aggressive behavior (29) . In contrast to choroid plexus carcinomas, the number of aberrations overall as well as of gains and losses on their own as identified by CGH bore no significance on survival among choroid plexus papillomas (30) .
Choroid Plexus Carcinoma
In a series of 15 choroid plexus carcinomas investigated by CGH, a significantly longer survival was associated with independent gain of 9p or loss of 10q (30) . Furthermore, analysis of DNA revealed that aneuploid choroid plexus carcinomas had a worse prognosis than diploid specimens and were associated with more aggressive behavior and 10-fold mortality (29) . In contrast, 2 further investigations on 13 and 28 cases, respectively, found that low S-phase fraction but not ploidy correlated with favorable outcome (31), or that there was no correlation between ploidy and outcome (32).
PINEAL PARENCHYMAL TUMORS
Pineal parenchymal tumors are rare neoplasms derived from pinocytes or their embryonal precursors and span a wide spectrum of differentiation that is paralleled by differences in biological behavior and clinical outcome. No molecular markers of prognostic value have been found yet. However, a CGH study on 9 pineal parenchymal tumors found that pineoblastomas and pineal parenchymal tumors of intermediate differentiation showed a similar extent of chromosomal imbalances per case (5.6 and 5.3, respectively), while high-level gains were exclusively found in pineoblastomas (10) . Furthermore, the youngest patient, a 1-year-old boy with pineoblastoma who died 33 months after diagnosis, showed most alterations with 7 chromosomal imbalances and accounted for 4 of the 5 high-level gains, indicating a potential prognostic role for chromosomal aberrations (10).
EMBRYONAL TUMORS
Embryonal CNS tumors are the most common group of malignant brain tumors in children and account for approximately 20% of brain neoplasms in that age group (7). Numerous publications describe efforts to identify the predictive value of various factors, but data appear to be controversial (8) .
Medulloblastoma
TP53:
In 1993, a study of 87 medulloblastomas found that intense nuclear overexpression of p53 protein was a harbinger of significantly reduced survival (p ϭ 0.002), and identified a group of patients with a 7-fold relative risk of death compared to all other cases (33) . This data was later corroborated by another cohort of 40 tumors, in which patients with specimens that stained intensely for p53 had a statistically significant decreased diseasefree survival (p ϭ 0.03) with 5-and 10-year survival rates of 45% and 0%, respectively (34) . Similarly, immunohistochemical detection of p53 protein in another series of 14 cases related to poor survival (p Ͻ 0.05) (35) , while among 2 groups of 10 children each with diseasefree survival or poor outcome resulting in death, only the latter group showed p53 expression (p ϭ 0.03) (36) .
Chemoresistance-Related Proteins, c-erbB2, ErbB-2, HER, and bcl-2:
Assessing the prognostic value of immunoexpression of the chemoresistance-related protein tenascin in 73 medulloblastomas, Korshunov et al found a close association with poor prognosis (p ϭ 0.008) with tumors showing tenascin expression and an apoptotic index Ն1.5% significantly prevailing among cases with metastatic dissemination (p ϭ 0.001), whereas expression of the c-erbB2 oncoprotein and epidermal growth factor receptor was found to be more typical for cases with local tumor recurrence (37) . The c-erbB2 oncogene product was also studied in another cohort of 55 childhood medulloblastomas, with the percentage of tumor cells expressing the c-erbB2 product proving to be a significant indicator of clinical outcome: patients with more than 50% positive tumor cells showed worse 10-year survival with only 10% vs 48% for those with under 50% positive cells (p Ͻ 0.005) (38) . In a study of 45 medulloblastoma in patients under 15 years of age, all children with cerbB2 expression died of their disease after an average of 1.2 years, revealing a highly significant correlation between c-erbB2 expression and survival (p ϭ 0.002) (39) . However, among 2 groups of 10 children each with disease-free survival or poor outcome resulting in death, neither expression of c-erbB2 nor bcl-2 had a correlation with outcome (36) . In a series of 70 cases, coexpression of HER2 and HER4 (two members of the EGFR family) showed independent prognostic significance resulting in a worse prognosis with increasing coexpression of the two (p ϭ 0.006), as well as with increasing HER2 expression alone (p ϭ 0.0039): while no patients positive for HER4 and with Ͼ50% HER2-positive tumor cells were alive after 5 years, 66% of patients negative for HER4 and with Ͻ50% HER2-positive tumor cells were still alive after a 25-year follow-up, with all other combinations showing intermediate survival (40) . Additionally, in a subgroup of 29 children with metastatic stage data, expression of either HER2 or HER4 receptor in Ͼ50% of tumor cells was significantly related to the presence of metastases (p ϭ 0.002 each) (40) . The same authors later investigated 48 medulloblastomas for the expression of the tyrosine kinase receptors ErbB-1, ErbB-2, ErbB-3, and ErbB-4, as well as for neuregulin 1-␣ and -␤ ligands, with expression of ErbB-2, ErbB-4, and neuregulin 1-␤ significantly related to the presence of metastases at diagnosis (p Ͻ 0.05) (41) . Later, Gilbertson et al analyzed 41 cases for ErbB-2 receptor expression and found reduced survival for high ErbB-2 receptor expression, with 5-year overall survival rates of 0% for high ErbB2 expression vs 66% with low expression (p ϭ 0.003) (42) . Most recently, an investigation of 38 classic, 30 nodular desmoplastic, and 18 large-cell/anaplastic medulloblastomas revealed ErbB-2 expression to be significantly more common in the latter group and to be independently associated with poor overall survival (p ϭ 0.031) and 5-year progression-free survival of 42% compared with 72% in ErbB-2-negative tumors (p ϭ 0.019) (43) . A combination of clinical characteristics and ErbB-2 expression provided an even higher accuracy in discriminating disease risk: 100% of 26 children with clinical average-risk (Ͼ3 years of age, non-metastatic, total or near-total tumor resection Յ1.5 cm 2 ) and ErbB-2-negative tumors were alive at 5 years compared with only 54% of the 13 children with average-risk and ErbB-2-positive tumors (p ϭ 0.0001) (43) . Finally, 3 studies of between 20 and 55 medulloblastomas found no relationship between bcl-2 staining and survival (36, 44, 45) .
N-myc and c-myc:
Investigating the potential prognostic role of the MYC proto-oncogene family, children with N-myc-positive medulloblastomas had a tendency (albeit not significant) towards poor outcome (p ϭ 0.1125), with N-myc-negative and GFAP-positive patients tending to survive N-myc-positive and GFAP-negative patients (46) . Similarly, in 2 recent series of 15 and 59 patients, amplifications of N-myc or L-myc seemed to indicate poor clinical outcome and tended to convey shorter survival, although statistical significance was also not reached in either study (47, 48) . Another investigation of 38 classic, 30 nodular desmoplastic, and 18 large cell/anaplastic tumors failed to find an association between N-myc or cmyc expression and prognosis (43) . However, in an earlier cohort of 32 patients, amplification of c-myc had been found to be the single worst prognostic parameter with tumors being resistant to therapy and all patients having fatal outcomes with a mean survival time of 9.3 months (p Ͻ 0.0001) (49), corroborating even earlier data from 18 cases, of which none of 3 patients with amplifications of MYC genes responded to therapy (50) . Moreover, amplification of oncogenes N-myc and c-myc among 72 cases appeared to predict rapid progression and aggressive course among medulloblastomas (51) . The same year, c-myc mRNA expression was shown to be an independent prognostic factor for unfavorable clinical outcome among 72 patients (p ϭ 0.025) (52) . Moreover, RT-PCR analysis of 26 medulloblastomas revealed low MYC mRNA expression to be an independent prognostic factor for progression-free (p ϭ 0.013) and overall survival outcome (p ϭ 0.034) with 5-year progression-free and overall survival of 92% vs 38% and 92% vs 45%, respectively (p ϭ 0.0048) (53) . The combination of low MYC mRNA expression and high TrkC mRNA expression in the same cohort identified a good outcome group of medulloblastoma patients with 100% progression-free survival after a median follow-up time of 55 months (p ϭ 0.066), with 3 of these 7 good outcome patients surviving without radiotherapy (53) . While immunoreactivity of c-myc in 68 cases did not show any differences between patients with various clinical outcomes and survival times (54) , in situ detection of c-myc mRNA among 59 medulloblastomas was significantly associated with shorter patient survival (p ϭ 0.04) (48) . Furthermore, although c-myc amplification occurred in only 5.2% of 77 tumors in another study, all patients died of clinically aggressive neoplasms within 7 months of diagnosis, also indicating that c-myc amplification may be a marker of poor prognosis (55) .
Neurotrophin 3 and TrkC:
In the mid-1990s, a study of 12 medulloblastomas for the expression of mRNA encoding neurotrophin 3 and its receptor TrkC found that patients with tumors expressing high levels of TrkC mRNA had significantly longer disease-free survival than those with low levels (p ϭ 0.01) and a more favorable overall survival (p ϭ 0.05), whereas no such correlation was found for TrkB (56) . Several years later, this was corroborated in a larger cohort of 42 childhood medulloblastomas, in which elevated expression of TrkC above median was associated with favorable clinical outcome as defined by progression-free (p ϭ 0.02) and overall survival (92 vs 39 months; p ϭ 0.0001), but with a trend toward metastatic disease (p ϭ 0.09) (57) . The authors reasoned that TrkC-mediated neurotrophin 3 signaling promotes apoptosis by activating multiple parallel signaling pathways and by inducing immediate-early gene expression of both c-jun and c-fos, thus supporting the notion that TrkC activation affects medulloblastoma outcome by inhibiting tumor growth through promotion of apoptosis (57) . The largest study yet consisting of 81 medulloblastomas and 6 supratentorial primitive neuroectodermal tumors (sPNET) also demonstrated an association between high TrkC mRNA expression and higher 5-year survival rate compared with low TrkC mRNA expression (89% vs 46%, respectively), especially among the 23 children under 3 years of age, in which the respective figures were 93% and 0% (p Ͻ 0.00005) (58) . When compared with established clinical prognostic factors and laboratory variables of potential prognostic significance, TrkC mRNA expression was found to be the single most powerful predictor of outcome (58) . In contrast, 2 recent investigations of TrkC immunoreactivity in 68 and 86 cases did not show any differences between patients' survival times and TrkC expression (43, 54) .
hTERT, MDR, PDGFRA, NEUROD3, and HIC-1:
When investigating the mRNA levels of the human telomerase reverse transcriptase (hTERT) in 36 medulloblastomas, a trend toward biologically aggressive tumor behavior and poor clinical outcomes in patients containing high levels was demonstrated, but due to short clinical follow-up the association was not statistically significant (p ϭ 0.078); hTERT was also found to be amplified in a recurrent tumor but not in the primary lesion, suggesting it can be involved in tumor progression (59) . Another group studied the P-glycoprotein-mediated multidrug resistance (MDR) gene in 29 cases and calculated a statistically significant inverse association between MDR expression and poor outcome (p ϭ 0.007), even among patients who received chemotherapy (p ϭ 0.036) (60) . Expression profiling and consecutive validation by immunohistochemistry in 23 medulloblastomas showed significant upregulation and overexpression of PDGFRA (platelet-derived growth factor receptor ␣) and SPARC (secreted protein and rich in cysteine) in metastatic compared with M0 tumors (p ϭ 0.00004 and 0.0025, respectively) (61) . Northern analysis and in situ hybridization of NEUROD3/neurogenin, a member of the basic helixloop-helix class of transcription factors playing a pivotal role in tissue-specific determination and differentiation, revealed that all of the 12 medulloblastomas presenting with distant metastases expressed NEUROD3 (p Ͻ 0.05) (62) . Finally, methylation of HIC-1 (hypermethylated in cancer), a putative tumor suppressor gene encoding for a zinc finger transcriptional repressor, beyond that seen in normal brain predicted poor overall survival independent of clinical risk category in 36 medulloblastomas (p ϭ 0.014) (63) .
DNA Ploidy: Regarding the influence of ploidy on medulloblastoma outcome, studies of approximately 200 cases have correlated diploid lesions with a more aggressive course and significantly greater tendency for distant metastases and death compared with better outcome for aneuploid tumors (64) (65) (66) (67) (68) . Three of these studies on 30 to 49 children demonstrated a better 8-year overall survival after subtotal resection (p Ͻ 0.01) (67) , and significantly improved outcome for aneuploid lesions (p ϭ 0.003) (66) , as well as worse 5-year survival of 48% in patients with diploid medulloblastomas compared with 89% in hyperdiploid tumors (p ϭ 0.04) (68) . One of these cohorts also contained 6 cases with bone metastases, of which 5 showed diploid and only 1 case showed aneuploid DNA, demonstrating that the incidence of bone metastases appears to correlate with DNA ploidy (p ϭ 0.046) (66) . In contrast, among 52 patients who received Ͼ50 Gy, those with diploid/tetraploid tumors had fewer recurrences than those with aneuploid tumors (p ϭ 0.03) (69) . Others have not found DNA ploidy to be an independent prognostic factor either way (60, 70) . Loss of Heterozygosity and CGH: Several investigations have assessed the influence of loss of heterozygosity (LOH) status on medulloblastoma outcome, with LOH of chromosome 17p found to be associated with worse overall survival and poor response to therapy (71) . Later studies of 56 (p ϭ 0.045) (72) and 18 patients (p Ͻ 0.05) (72) showed significant relationships between LOH 17p and shortened overall survival, indicating that LOH 17p may be used as a prognostic biological marker. Furthermore, LOH 17p was associated with metastatic disease and significantly worse event-free survival in 30 cases (p Ͻ 0.01); however, the prognosis of these tumors was only worse when amplification of c-myc was also identified: all of these tumors were resistant to therapy and had fatal outcomes (49). However, in series of 21 and 56 medulloblastomas, respectively, no significant association was found between 17p LOH/deletion and shorter survival (74) or higher metastatic stage (75) . Another comparative study of 17 classic and 14 desmoplastic medulloblastomas corroborated the lack of prognostic value of Ϫ17p (p ϭ 0.94), but found a significantly worse outcome for cases with loss of chromosome 22 (p ϭ 0.0013) (76) . More recently, among 2 groups of 10 children each with disease-free survival or poor outcome resulting in death, presence of isochromosome 17q in FISH had no correlation with outcome (36) . This was underscored in a later study of 41 medulloblastomas that were analyzed for aberrations of chromosome 17 and presented with deletions of 17p in 49% of tumors (42) . Loss of 17p occurred either in isolation (20%) or in association with ϩ17q (29%, compatible with isochromosome 17q), with isolated 17p loss posing as a significant negative prognostic factor (p ϭ 0.003), in particular after stratification of cases into high risk showing high ErbB2 expression and/or isolated 17p loss and low risk patients with neither aberration (p ϭ 0.0001) (42) . Interestingly, and supporting findings that LOH at 17p is associated with poor clinical outcome, 17p loss in a series of 33 cases was only encountered in large cell/anaplastic medulloblastomas (77) . A relationship between ϩ17q and survival, however, could not be confirmed (47) . Finally, 2 CGH studies found that acquisition of genetic alterations (i.e. the number of chromosomal changes, is associated with unfavorable prognosis in patients with medulloblastomas [78] ), whereas the other detected significantly more aberrations in large cell/anaplastic medulloblastomas compared with non-anaplastic ones (6.8 vs 3.3/case) (77) .
Gene Expression Profiling: In 2 recent publications gene expression profiles of medulloblastomas identified a number of genes not previously associated with clinical outcome (5, 79) . Among a set of 60 cases, those correlating with a favorable outcome included genes characteristic of cerebellar differentiation (e.g. vesicle coat protein, ß-NAP, NSCL1, TRKC, and sodium channels), as well as genes encoding extracellular matrix proteins such as PLOD lysyl hydroxylase, collagen type V ␣1, and elastin. In contrast, cerebellar differentiation genes were underexpressed in poor prognosis tumors that were dominated by the expression of genes related to cell proliferation and metabolism (MYBL2, enolase 1, LDH, HMG1(Y), cytochrome C oxidase) and multidrug resistance (sorcin), as well as a number of ribosomal proteinencoding genes (5) . Using an 8-gene outcome prediction pattern, patients predicted to be survivors according to the above expression profile had a 5-year overall survival of 80% vs 17% (p ϭ 0.000003); furthermore, medulloblastomas were also found to be molecularly distinct from sPNET, AT/RT, and malignant gliomas (5) . The second study on 55 cases demonstrated gene expression profiles to be the only significant clinical prognostic factor (p ϭ 0.03), with gene expression profiles predicting outcome independent of other criteria (79) . The hazard for death in the low-risk gene expression group was found to be 66% lower than that for patients in the high-risk group, with the 8 genes predictive of outcome being apolipoprotein D, KIAA0220 gene, extracellular matrix protein PLOD lysyl hydroxylase, and vesical coat protein ß-NAP as markers of survival as well as ribosomal proteins L7a, S10 and S18 and cellular proliferation gene MYBL2 V-myb as markers of treatment failure; however, a trend (p ϭ 0.08) for worse prognosis was noted for a subset of low-risk patients with metastatic disease at presentation (79) .
Supratentorial PNET: Supratentorial primitive neuroectodermal tumors (sPNET) are rare embryonal neoplasms and account for just 1.9% of pediatric brain neoplasms (7). So far, only 1 study has subdivided 6 sPNET from 81 medulloblastomas; however, the final findings regarding an association between high TrkC mRNA expression and higher 5-year survival rate of 89% compared with 46% for low TrkC mRNA expression were not listed separately (58) . Thus, although a trend for a worse outcome for sPNET compared with medulloblastomas has been observed, no exclusive molecular prognostic markers have been found for sPNET.
Atypical Teratoid/Rhabdoid Tumor, Medulloepithelioma, Ependymoblastoma, Medullomyoblastoma: No molecular markers of prognostic value have been found yet.
GLIAL TUMORS OF UNCERTAIN ORIGIN, NEURONAL AND MIXED NEURONAL-GLIAL TUMORS, MELANOCYTIC LESIONS, GERM CELL TUMORS, CRANIOPHARYNGIOMAS
No molecular markers of prognostic value have been found yet.
TUMORS OF THE HEMATOPOIETIC SYSTEM Langerhans Cell Histiocytosis
Langerhans cell histiocytosis (LCH) typically occurs in children with a mean of 12 years and usually presents as a solitary osteolytic lesion of the skull. In 4 series, no correlation between DNA ploidy and prognosis was encountered among 97 pediatric patients with LCH (reviewed in [80] ).
CONCLUSIONS
In their scathing assessment of the published literature on prognostic and predictive factors in cancer, Hall and Going come to the conclusion that much of it is of poor quality and often triggered by the availability of a new reagent rather than a compelling hypothesis calling for robust testing (81) . They continue that ''even in controlled experimental systems, predicting behavior is difficult; however, without rigorous objective strategies, poor studies will continue to obscure rather than clarify the contribution of potential markers'' and that ''poor quality has given the analysis of prognostic factors a deservedly bad reputation'' (81). Thus, it comes as no surprise that despite an extensive literature on the clinical value of molecular markers in cancer, few have made the transition into clinical practice, mainly because of biological and methodological issues. The biological issues relate to the complexity of cellular processes and their dysregulation in cancer: the cumulative acquisition of multiple abnormalities in neoplastic cells implies that the status of a single molecular marker is unlikely to forecast the behavior of a tumor. Methodological issues can also cause problems in the assessment of potential prognostic indicators, reducing the credibility of research data. Weaknesses include failure to test clearly formulated hypotheses, inadequate sample size, inappropriate significance testing, arbitrary definition of patient groups, inadequately reproducible assays, and failure to verify prognostic factors with data independent of the one which suggested the original hypothesis. This situation will persist until critical attention is paid to study design and prospective validation of supposed predictive factors, without which the flood of data from new molecular technologies will not be used effectively.
This survey of prognosis-related molecular features in childhood brain tumors revealed a number of significant associations and potential harbingers of prognosis, some of which are promising for future applicability. However, for the above reasons some of these correlations must be considered cautiously and none are currently in clinical use. This is mainly due to data accumulation from relatively small cohorts, which renders a valid multivariate statistical approach impossible or at least meaningless. Furthermore, investigations have been almost exclusively performed retrospectively and, because of the scarcity of pediatric CNS neoplasms in most institutional series, patient and tissue accrual had to be performed over a long period of time, thus jeopardizing a homogeneous study population as therapy regimens and neuropathological classification schemes have changed over time. To exemplify this point, Biegel et al in their study of the prognostic significance of chromosome 17p deletions in medulloblastomas calculated that identification of a meaningful difference in relapse-free survival would require a sample size of 122 cases for an adequate, firm, and valid multivariate analysis that can adjust for and take into account different variables such as age, metastatic state, extent of surgery, adjuvant therapy, etc. (75) . The current review encountered no investigation with a study population above this threshold and only 1 study with over 100 cases ( Table 2) .
With uncommon neoplasms such as pediatric brain tumors, the only way forward to the accrual of large cohorts and subsequent stratification and validation of prognosis-relevant factors is prospective sampling of sufficient cases in the context of multicenter clinical trials with reference diagnosis by experienced pediatric (neuro-)pathologists, treatment according to standardized therapy regimens, as well as collection and registration of all relevant demographic, clinical, and pathologic data in centralized bodies or institutions such as the Children's Cancer Study Group (CCG) and Pediatric Oncology Group (POG) in the US or the Gesellschaft für pädiatrische Onkologie und Hämatologie (GPOH, Society for Pediatric Oncology and Hematology) and Deutsches Kinderkrebsregister (German Childhood Cancer Registry) (7) in Germany. These structures necessitate a high degree of organization, cooperation, motivation, and dedication by all parties involved but will-in contrast to small institutional series-more likely yield (and already have, see references [4] and [20] ) statistically sound and clinically relevant data. Thus, molecular genetic analyses hold promise in stratifying and refining the management of children with malignant brain tumors. An important step in the application of these techniques to guide clinical decision-making involves transitioning these approaches from the research setting into the clinical diagnostic arena, using methods that can be performed rapidly and reliably on surgically obtained tumor specimens. It is likely that the current limited portfolio of prognostic markers will be increased substantially during the next several years as innovative techniques for tumor genotyping and gene expression profiling help to identify additional correlates of tumor prognosis. Therefore, the application of discoveries and techniques of molecular biology has great potential to unlock the mysteries of neuro-oncogenesis and could influence therapeutic decision-making as well as provide an impetus for the development of new interventions.
It is hoped that this review will encourage others to study some of the proposed clinically relevant factors, so that it may be possible in the future to apply a panel of molecular markers in order to facilitate prognostic and
